MSB 0.52% 95.5¢ mesoblast limited

Ann: FDA Grants Rare Pediatric Disease Designation for Revascor, page-76

  1. 131 Posts.
    lightbulb Created with Sketch. 19
    Wow, MSB really leading the way (joke):

    Longeveron Granted Orphan Drug Designation by FDA for Lomecel-B to Treat Infants with Hypoplastic Left Heart Syndrome (HLHS)

    December 6, 2021

    • HLHS is a rare congenital heart defect that affects approximately 1,000 babies in the U.S. per year
    • Orphan Drug Designation confers certain benefits and may result in seven year market exclusivity upon approval for this indication if all statutory and regulatory requirements are met
    • Supplements Rare Pediatric Disease Designation recently granted by FDA

    MIAMI, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.5¢
Change
-0.005(0.52%)
Mkt cap ! $1.096B
Open High Low Value Volume
95.5¢ 97.0¢ 95.0¢ $329.8K 345.1K

Buyers (Bids)

No. Vol. Price($)
25 174779 95.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.5¢ 33729 16
View Market Depth
Last trade - 10.43am 13/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.